Cookies Policy

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.

I accept this policy

Find out more here

A new spherically agglomerated drug composite system with lactose for dry powder inhalation

No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.
The full text of this article is not currently available.

Brill’s MyBook program is exclusively available on BrillOnline Books and Journals. Students and scholars affiliated with an institution that has purchased a Brill E-Book on the BrillOnline platform automatically have access to the MyBook option for the title(s) acquired by the Library. Brill MyBook is a print-on-demand paperback copy which is sold at a favorably uniform low price.

This Article is currently unavailable for purchase.
Add to Favorites
You must be logged in to use this functionality

In order to prepare a dry powder inhalation (DPI) formulation for steroids, we designed crystal agglomerates consisting of fine drug crystals suitable for DPI that disintegrated into primary crystals in the inhalation device at emission. Using these agglomerates, we developed a new spherically agglomerated drug composite system with lactose for DPI of steroids with a Jethaler®. The drug agglomerates were prepared by the method of spherical agglomeration in liquid with control of the particle size of the primary drug crystal, agglomerates and mechanical strength of agglomerates by changing the agitation speed of the agglomeration system before (5°C-1000 r.p.m.) and after (5°C-300 r.p.m.) the dispersing medium was saturated with bridging liquid. The agglomerates in the DPI formulation disintegrated into respirable primary crystals by collision with coformulated lactose particles in the milling chamber of the device when inhaled. The DPI formulation with these agglomerates exhibited a higher fine particle (= respirable) fraction (FPF: 24.5%) than the formulation with fine drug particles (FPF: 16.1%) as evaluated in vitro with a cascade impactor. The inhalation property of the present DPI formulation was determined by the particle size of coformulated lactose particles. It was found that 325M lactose (approximately 60 μm mean diameter) was most suitable to improve the inhalation properties of the present system.


Full text loading...


Data & Media loading...

Article metrics loading...



Can't access your account?
  • Key

  • Full access
  • Open Access
  • Partial/No accessInformation